MCID: CHL066
MIFTS: 51

Cholangitis

Categories: Gastrointestinal diseases, Immune diseases

Aliases & Classifications for Cholangitis

MalaCards integrated aliases for Cholangitis:

Name: Cholangitis 12 54 44 15 70 32

Classifications:



External Ids:

Disease Ontology 12 DOID:9446
ICD9CM 34 576.1
MeSH 44 D002761
NCIt 50 C26718
SNOMED-CT 67 155831003
ICD10 32 K83.0
UMLS 70 C0008311

Summaries for Cholangitis

Disease Ontology : 12 A bile duct disease that is an inflammation of the bile duct.

MalaCards based summary : Cholangitis is related to ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis and sclerosing cholangitis, neonatal. An important gene associated with Cholangitis is CLDN1 (Claudin 1), and among its related pathways/superpathways are Salmonella infection (KEGG) and Selenium Micronutrient Network. The drugs Ceftriaxone and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include liver, pancreas and t cells, and related phenotypes are digestive/alimentary and liver/biliary system

Related Diseases for Cholangitis

Diseases in the Cholangitis family:

Autoimmune Cholangitis Acute Cholangitis
Chronic Cholangitis

Diseases related to Cholangitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1039)
# Related Disease Score Top Affiliating Genes
1 ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis 33.3 CLDN16 CLDN1
2 sclerosing cholangitis, neonatal 32.9 KAAG1 DCDC2 CLDN1
3 ascending cholangitis 32.5 GPT F2 CRP ALB
4 suppurative cholangitis 32.3 GPT DLAT CRP ABCB4
5 cholecystitis 32.1 GPT F2 ALB ABCB4
6 bile duct cancer 31.9 IL6 GPT CEACAM5 ALB
7 acute cholangitis 31.9 IL6 GPT F2 CRP CEACAM5 ALB
8 primary biliary cholangitis 31.7 NR1H4 HLA-DRB1 GPT GPBAR1 F2 DLAT
9 ulcerative colitis 31.6 TNF IL6 HLA-DRB1 CRP
10 autoimmune hepatitis 31.4 TNF HLA-DRB1 GPT F2 DLAT ALB
11 cholangitis, primary sclerosing 31.4 TNF NR1H4 MIR222 IL6 GPT GPBAR1
12 autoimmune pancreatitis 31.4 TNF HLA-DRB1 CFTR CA2 ALB
13 cholestasis 31.4 NR1H4 GPT F2 ALB ABCB4 ABCB11
14 sclerosing cholangitis 31.2 TNF NR1H4 MIR222 KAAG1 IL6 HLA-DRB1
15 pancreatitis 31.1 TNF IL6 CRP CFTR CA2
16 liver cirrhosis 31.1 TNF IL6 HLA-DRB1 GPT F2 CRP
17 autoimmune disease 31.0 TNF IL6 HLA-DRB1 DLAT CRP
18 crohn's disease 31.0 TNF IL6 HLA-DRB1 CRP ALB
19 portal hypertension 31.0 TNF NR1H4 GPT F2 CFTR ALB
20 choledocholithiasis 31.0 GPT F2 CRP CEACAM5 ALB ABCB4
21 varicose veins 31.0 TNF IL6 F2
22 pericholangitis 31.0 ABCB4 ABCB11
23 echinococcosis 30.9 TNF IL6 HLA-DRB1
24 afferent loop syndrome 30.9 GPT ALB
25 obstructive jaundice 30.9 TNF IL6 GPT GPBAR1 F2 CRP
26 acute pancreatitis 30.9 TNF IL6 GPT CRP CFTR
27 esophageal varix 30.9 GPT F2 ALB
28 biliary atresia 30.8 NR1H4 GPT F2 ALB ABCB4 ABCB11
29 inflammatory bowel disease 30.8 TNF NR1H4 IL6 HLA-DRB1 F2 CRP
30 acute kidney failure 30.8 GPT F2 ALB
31 hepatic coma 30.8 GPT F2 ALB
32 acquired immunodeficiency syndrome 30.7 TNF IL6 CRP ALB
33 graft-versus-host disease 30.7 TNF IL6 HLA-DRB1
34 bile duct cysts 30.7 GPT CEACAM5 ALB ABCB4 ABCB11
35 cholelithiasis 30.6 NR1H4 GPT CRP ALB ABCB4
36 diarrhea 30.6 TNF IL6 GPT CFTR ALB
37 thyroiditis 30.6 TNF IL6 HLA-DRB1 CRP
38 acalculous cholecystitis 30.6 GPT F2 CRP ALB
39 gallbladder cancer 30.6 TNF IL6 CRP CEACAM5 ABCB4
40 liver disease 30.6 TNF NR1H4 IL6 GPT F2 DLAT
41 duodenal ulcer 30.5 TNF IL6 HLA-DRB1
42 hepatitis a 30.5 TNF GPT F2 ALB
43 klatskin's tumor 30.5 GPT F2 CEACAM5 ALB
44 bacterial infectious disease 30.4 TNF IL6 CRP CFTR
45 hepatitis e 30.4 TNF GPT F2 ALB
46 toxic shock syndrome 30.4 TNF IL6 CRP
47 celiac disease 1 30.4 TNF IL6 HLA-DRB1 GPT CRP ALB
48 hepatic encephalopathy 30.4 TNF IL6 GPT F2 ALB
49 disseminated intravascular coagulation 30.4 TNF IL6 GPT F2 CRP
50 amyloidosis 30.3 TNF IL6 CRP ALB

Comorbidity relations with Cholangitis via Phenotypic Disease Network (PDN): (show all 16)


Acute Cystitis Acute Pancreatitis
Cholecystitis Cholestasis
Deficiency Anemia Familial Atrial Fibrillation
Gallbladder Cancer Heart Disease
Hepatitis Intrahepatic Gall Duct Cancer
Pancreatic Cancer Pancreatitis, Hereditary
Paralytic Ileus Postcholecystectomy Syndrome
Primary Biliary Cholangitis Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Cholangitis:



Diseases related to Cholangitis

Symptoms & Phenotypes for Cholangitis

MGI Mouse Phenotypes related to Cholangitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 ABCB4 ALB CA2 CFTR F2 IL6
2 liver/biliary system MP:0005370 9.23 ABCB11 ABCB4 ALB CFTR GPBAR1 IL6

Drugs & Therapeutics for Cholangitis

Drugs for Cholangitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 137)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185
5
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
6
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
7
Teicoplanin Approved, Investigational Phase 4 61036-62-2
8
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
9
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
10
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
11
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
12
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
15
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
16
Mycophenolic acid Approved Phase 4 24280-93-1 446541
17
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
18 Cytochrome P-450 Enzyme Inhibitors Phase 4
19 Gastrointestinal Agents Phase 4
20 Hormones Phase 4
21 Anti-Inflammatory Agents Phase 4
22 Hormone Antagonists Phase 4
23 glucocorticoids Phase 4
24 Antiemetics Phase 4
25 Antineoplastic Agents, Hormonal Phase 4
26 Neuroprotective Agents Phase 4
27 Protective Agents Phase 4
28 Anti-Infective Agents Phase 4
29 Antiparasitic Agents Phase 4
30 Alkylating Agents Phase 4
31 Antiprotozoal Agents Phase 4
32 Sulperazone Phase 4
33 Antirheumatic Agents Phase 4
34 Immunologic Factors Phase 4
35 Dermatologic Agents Phase 4
36 Immunosuppressive Agents Phase 4
37 Antitubercular Agents Phase 4
38 Methylprednisolone Acetate Phase 4
39 Antifungal Agents Phase 4
40 Cyclosporins Phase 4
41 Calcineurin Inhibitors Phase 4
42 Anti-Bacterial Agents Phase 4
43 Antibiotics, Antitubercular Phase 4
44
Simvastatin Approved Phase 3 79902-63-9 54454
45
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
46
Bezafibrate Approved, Investigational Phase 3 41859-67-0 39042
47 Anticholesteremic Agents Phase 3
48 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
49 Antimetabolites Phase 3
50 Hypolipidemic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 198)
# Name Status NCT ID Phase Drugs
1 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Unknown status NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
3 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Randomized Multi-center Study Completed NCT01744847 Phase 4
4 Clinical Research of Reducing Medication Regimen for Ursodeoxycholic Acid in Treatment of Stable Primary Biliary Cholangitis Recruiting NCT04650243 Phase 4 ursodeoxycholic acid
5 Randomized Trial of Short Antibiotic Course to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
6 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
7 Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II:A Randomized Controlled Open-label Clinical Trial Recruiting NCT04617561 Phase 4 Ursodeoxycholic acid;Ursodeoxycholic acid+Low Dose Glucocorticoid(Methylprednisolone)
8 A Randomized Controlled Open-label Clinical Trial of Ursodeoxycholic Acid Combined With Total Glucosides of Paeony in the Treatment of PBC With AIH Features 1 Recruiting NCT04618575 Phase 4 Ursodeoxycholic acid combined with total glucosides of paeony;Ursodeoxycholic acid only
9 A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment Active, not recruiting NCT03633227 Phase 4 Obeticholic Acid (OCA);Placebo
10 Antibiotics Treatment of Cholangitis Post-Kasai Portoenterostomy Not yet recruiting NCT04370145 Phase 4 Sulperazon;Teicoplanin;Meropenem Injection
11 Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy Not yet recruiting NCT04376528 Phase 4 Cyclosporin A;Mycophenolate Mofetil
12 Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality Terminated NCT02034279 Phase 4 Albumin
13 Multicenter Randomized Trial Comparing Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
14 The Effect of Bezafibrate on Cholestatic Itch Unknown status NCT02701166 Phase 3 Bezafibrate;Placebo
15 Probiotics in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease- a Randomized Placebo-Controlled Cross-Over Trial Unknown status NCT00161148 Phase 3 Probiotics
16 Multicentered Randomized Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
17 Digital SpyGlass Cholangioscopy Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
18 Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects Completed NCT01802073 Phase 3 Oral Vancomycin
19 A Prospective, Randomized, Multi-centered, Placebo-controlled Clinical Trial of Oral Vanycomycin in Adults With Primary Sclerosing Cholangitis Recruiting NCT03710122 Phase 2, Phase 3 Vancomycin
20 Effect of Simvastatin on the Prognosis of Primary Sclerosing Cholangitis (PSC); A Randomized, Double-blind, Placebo Controlled Multicenter Study Recruiting NCT04133792 Phase 3 Simvastatin 40mg;Placebo oral tablet
21 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis Recruiting NCT03890120 Phase 3 Cilofexor;Placebo
22 Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing norUrsodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Recruiting NCT03872921 Phase 3 norUrsodeoxycholic Acid
23 RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Recruiting NCT04620733 Phase 3 Seladelpar 10 mg;Placebo;Seladelpar 5 mg
24 Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis Recruiting NCT04167358 Phase 3 Linerixibat
25 A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid Recruiting NCT04526665 Phase 3 Elafibranor 80mg;Placebo
26 ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) Recruiting NCT03301506 Phase 3 Seladelpar 5 mg Capsule;Seladelpar 10 mg Capsule
27 The Safety and Efficacy of a Short Specially Designed Fully Covered Metallic Stent in the Management of Benign Post-surgical Biliary Strictures: a Randomized-controlled Study Recruiting NCT03716232 Phase 3
28 Safety and Efficacy of Bezafibrate Plus Ursodesoxicolic Acid in Patients With Primary Biliary Cholangitis Without Response Active, not recruiting NCT04751188 Phase 3 Bezafibrate 200 MG Oral Tablet;Placebo;Ursodeoxycholic Acid
29 Double Blind, Multicentric, Randomized, Placebo-controlled Trial, Evaluating the Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy Not yet recruiting NCT04309773 Phase 3 Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy;Placebo of Bezafibrate in addition to standard UDCA therapy
30 A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Suspended NCT03602560 Phase 3 seladelpar 5-10 mg;seladelpar 10 mg;Placebo
31 A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease Withdrawn NCT03035058 Phase 3 Vedolizumab;Placebo
32 Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis Unknown status NCT01688024 Phase 2 Mitomycin C;Normal saline
33 A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT01672853 Phase 2
34 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis. Completed NCT02424175 Phase 1, Phase 2
35 Investigation of the Activity of Vidofludimus Calcium, a Novel, Orally Available, Small Molecule Inhibitor of Dihydroorotate Dehydrogenase, as a Treatment for Primary Sclerosing Cholangitis (PSC) Completed NCT03722576 Phase 2 Vidofludimus calcium
36 A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis Completed NCT02704364 Phase 2
37 PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT02653625 Phase 2 Cenicriviroc 150 mg
38 A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC). Completed NCT02239211 Phase 2 BTT1023
39 A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis Completed NCT02061540 Phase 2 LUM001
40 Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis Completed NCT01755507 Phase 2 norUDCA;Placebo
41 Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis Completed NCT00004762 Phase 2 cladribine
42 An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis Completed NCT02978339 Phase 1, Phase 2 Curcumin
43 A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC) Completed NCT03333928 Phase 2 HTD1801;Placebo
44 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis Completed NCT02177136 Phase 2 OCA;Placebo
45 A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis Completed NCT02943460 Phase 2 Cilofexor;Placebo to match Cilofexor
46 A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis Completed NCT02516605 Phase 2 Part 1: LJN452;Part 1: Placebo;Part 2: LJN452 Dose level 1;Part 2: Placebo;Part 2: LJN452 Dose level 2
47 A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA) Completed NCT03394924 Phase 2 EDP-305 Dose 1;EDP-305 Dose 2;Placebo
48 Antibiotic Prophylaxis for ERCP: a Comparison of Intravenous Ceftriaxone With Intravenous Moxifloxacin in the Prophylaxis of Cholangitis Completed NCT02098486 Phase 2 Moxifloxacin;ceftriaxone
49 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80 mg and 120mg After 12 Weeks of Treatment in Patients With Primary Biliary Cholangitis and Inadequate Response to Ursodeoxycholic Acid Completed NCT03124108 Phase 2 Elafibranor 80 mg;Elafibranor 120 mg;Placebo
50 An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With a 44-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA) Completed NCT02955602 Phase 2 MBX-8025 2 mg Capsule;MBX-8025 5 mg Capsule;MBX-8025 10 mg Capsule

Search NIH Clinical Center for Cholangitis

Cochrane evidence based reviews: cholangitis

Genetic Tests for Cholangitis

Anatomical Context for Cholangitis

MalaCards organs/tissues related to Cholangitis:

40
Liver, Pancreas, T Cells, Kidney, Colon, Lung, Bone

Publications for Cholangitis

Articles related to Cholangitis:

(show top 50) (show all 15385)
# Title Authors PMID Year
1
Induction of autoimmune cholangitis in non-obese diabetic (NOD).1101 mice following a chemical xenobiotic immunization. 61 54
19094117 2009
2
Preoperative determinants of common bile duct stones during laparoscopic cholecystectomy. 54 61
17887996 2008
3
Preoperative clinical and paraclinical predictors of choledocholithiasis. 54 61
18522887 2008
4
Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. 61 54
17539998 2007
5
Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4. 61 54
15258199 2004
6
[Usefulness of endoscopic cholangiography and sphincterotomy in patients with biliary lithiasis]. 61 54
15765973 2004
7
Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions. 54 61
15026266 2004
8
Autoimmune liver disease. 61 54
15703563 2003
9
Role of preoperative endoscopic retrograde cholangio pancreaticography in the management of mild to moderate acute biliary pancreatitis. 54 61
19861798 2002
10
Cysteinyl leukotrienes in the bile of patients with obstructive jaundice. 61 54
12424566 2002
11
Autoimmune cholangitis within the spectrum of autoimmune liver disease. 61 54
10827147 2000
12
Autoimmune liver disease. 61 54
17023884 2000
13
Secretory low-molecular-weight phospholipases A2 and their specific receptor in bile ducts of patients with intrahepatic calculi: factors of chronic proliferative cholangitis. 61 54
10094942 1999
14
Different susceptibility of mice to immune-mediated cholangitis induced by immunization with carbonic anhydrase II. 61 54
9605187 1998
15
Antibodies to carbonic anhydrase in patients with immune cholangiopathies. 61 54
7768386 1995
16
Review article: safety of new biologic agents for inflammatory bowel disease in the liver. 61
33470695 2021
17
Long-term kidney and liver outcome in 50 children with autosomal recessive polycystic kidney disease. 61
33165639 2021
18
Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis. 61
32558699 2021
19
Deletion of Mcpip1 in Mcpip1fl/flAlbCre mice recapitulates the phenotype of human primary biliary cholangitis. 61
33513427 2021
20
Immunoglobulin G4-Related Sclerosing Cholangitis Revealed by 68Ga-FAPI PET/MR. 61
33630803 2021
21
Prognosis of Primary Sclerosing Cholangitis According to Age of Onset. 61
33811469 2021
22
Associations of neopterin and kynurenine-tryptophan ratio with survival in primary sclerosing cholangitis. 61
33583308 2021
23
Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis. 61
33608929 2021
24
Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis. 61
33428478 2021
25
Fully automated detection of primary sclerosing cholangitis (PSC)-compatible bile duct changes based on 3D magnetic resonance cholangiopancreatography using machine learning. 61
32974688 2021
26
Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent. 61
33231850 2021
27
Issues to be considered to address the future liver remnant prior to major hepatectomy. 61
32894345 2021
28
Surgically resected hepatic mass caused by fascioliasis. 61
33471251 2021
29
Suppression of systemic inflammation and signs of acute and chronic cholangitis by multi-kinase inhibitor 1-(4-Cl-benzyl)-3-chloro-4-(CF3-phenylamino)-1H-pyrrole-2,5-dione. 61
33792809 2021
30
Fasciola As An Unusual Cause of Cholangitis. 61
32147590 2021
31
Rodent models of cholestatic liver disease: A practical guide for translational research. 61
33486884 2021
32
Breakdown in hepatic tolerance and its relation to autoimmune liver diseases. 61
33793157 2021
33
Implications of gut microbiota in autoimmune liver diseases. 61
33793160 2021
34
Evaluation of circulating cell-free DNA in cholestatic liver disease using liver-specific methylation markers. 61
33794792 2021
35
NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice. 61
33506599 2021
36
Effects of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the United Kingdom. 61
32562892 2021
37
A case of a smooth transition to subsequent percutaneous transjejunal biliary intervention for hepatolithiasis after biliary reconstruction by adding jejunostomy during an emergency operation for perforation due to balloon-assisted endoscopy. 61
33400187 2021
38
Role of Prophylactic Cholecystectomy After Endoscopic Sphincterotomy for Biliary Stone Disease: A Systematic Review and Meta-analysis. 61
32590541 2021
39
Nanoparticle-mediated targeting of autoantigen peptide to cross-presenting liver sinusoidal endothelial cells protects from CD8 T-cell-driven autoimmune cholangitis. 61
33346377 2021
40
IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression. 61
33197512 2021
41
Treatment outcomes, including risk factors of stone recurrence, for hepatolithiasis using balloon-assisted endoscopy in patients with hepaticojejunostomy (with video). 61
33140150 2021
42
Safety and Efficacy of Endoscopic Retrograde Cholangiopancreatography in Patients with Performance Status 4. 61
32440744 2021
43
Pembrolizumab-related sclerosing cholangitis manifested by a pruned-tree appearance of the bile ducts. 61
33164060 2021
44
Comment on the management of liver hydatid cyst with cystobiliary communication and acute cholangitis: a 27-year experience. 61
33587153 2021
45
Total Laparoscopic Resection of Hilar Cholangiocarcinoma Type 3b: Applying a Parachute Technique for Hepaticojejunostomy. 61
33000370 2021
46
Real-world experience with obeticholic acid in patients with primary biliary cholangitis. 61
33681748 2021
47
Determining the factors affecting serum presepsin level and its diagnostic utility: A cross-sectional study. 61
33454214 2021
48
Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort. 61
33577739 2021
49
Restoration of portal flow with varix in liver transplantation for patients with total portal vein thrombosis: an effective strategy in the largest center experience. 61
33797802 2021
50
Post-partum Primary Biliary Cholangitis Preceded by Intrahepatic Cholestasis of Pregnancy in Three First Nation Patients. 61
32440749 2021

Variations for Cholangitis

Expression for Cholangitis

Search GEO for disease gene expression data for Cholangitis.

Pathways for Cholangitis

GO Terms for Cholangitis

Cellular components related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 basolateral plasma membrane GO:0016323 9.56 CLDN1 CEACAM5 CA2 ABCB11
2 apical plasma membrane GO:0016324 9.35 CLDN1 CFTR CEACAM5 ABCB4 ABCB11
3 extracellular space GO:0005615 9.28 TNF MIR222 IL6 HLA-DRB1 GPT F2
4 intercellular canaliculus GO:0046581 9.16 ABCB4 ABCB11

Biological processes related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 TNF MIR222 HLA-DRB1 GPBAR1
2 acute-phase response GO:0006953 9.5 IL6 F2 CRP
3 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.43 NR1H4 HLA-DRB1 CFTR
4 vascular endothelial growth factor production GO:0010573 9.37 TNF IL6
5 positive regulation of JAK-STAT cascade GO:0046427 9.33 TNF IL6 F2
6 negative regulation of lipid storage GO:0010888 9.13 TNF IL6 CRP
7 cellular response to bile acid GO:1903413 8.8 NR1H4 GPBAR1 ABCB4

Molecular functions related to Cholangitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.13 CFTR ABCB4 ABCB11
2 bile acid receptor activity GO:0038181 8.62 NR1H4 GPBAR1

Sources for Cholangitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....